Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cns Pharmaceuticals Inc (CNSP)
Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cns Pharmaceuticals Inc 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 USA

www.cnspharma.com P: 800-946-9185

Description:

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is based in Houston, United States.

Key Statistics

Overview:

Market Capitalization, $K 1,779
Enterprise Value, $K -8,281
Shares Outstanding, K 6,215
Annual Sales, $ 0 K
Annual Net Income, $ -15,270 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,520 K
EBIT, $ -18,990 K
EBITDA, $ -18,980 K
60-Month Beta 2.65
% of Insider Shareholders 3.88%
% of Institutional Shareholders 4.72%
Float, K 5,973
% Float 96.12%
Short Volume Ratio 0.29

Growth:

1-Year Return -82.84%
3-Year Return -99.64%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.08 on 11/14/23
Latest Earnings Date 04/01/24
Earnings Per Share ttm -4.71
EPS Growth vs. Prev Qtr -3.85%
EPS Growth vs. Prev Year -299.96%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 11/29/22

CNSP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -603.40%
Return-on-Assets % -254.54%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.41
Interest Coverage -1,526.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar